APhA looks back on 2013, forward to 2014 as group aims for provider status for pharmacists
WASHINGTON — Serious discussion about the possibility of officially granting healthcare provider status to pharmacists is among the achievements that a pharmacy professional group cited as it welcomed the new year.
In a statement released on New Year’s Day, American Pharmacists Association EVP and CEO Thomas Menighan wrote that while a proposed amendment to the sustainable growth rate bill in 2013 to grant pharmacists provider status wasn’t introduced or approved, "we can officially say that the topic of provider status for pharmacists is being discussed in the Senate."
Menighan wrote that the APhA would continue pushing for provider status for pharmacists and developing a standard patient care process, noting that the profession has been lacking in that area, unlike standardized processes for medicine and nursing. "[But] we’re poised to fix that," he wrote, adding that the group is also working with the Joint Commission of Pharmacy Practitioners to develop a vision statement to further define the future of pharmacy practice.
Teva launches authorized generic version of Pfizer’s Detrol LA
JERUSALEM — Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.
Teva announced the launch of authorized generic tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths. Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under contracts between the branded manufacturers and third-party companies.
The drug is a version of Pfizer’s Detrol LA, which had sales of about $571.5 million during the 12-month period that ended in September, according to IMS Health.
Salix purchase of Santarus completed
RALEIGH, N.C. — Salix Pharmaceuticals has completed its $2.6 billion acquisition of Santarus, Salix said.
The drug maker announced that it had completed the $32-per-share acquisition of Santarus, which the companies announced in November. The combination of the companies’ product portfolios includes 22 marketed products, such as Xifaxan, Glumetza, Zegerid, Relistor and others.
"The acquisition of Santarus is a transformational event for Salix and an important milestone in our growth as the leading gastroenterology-focused specialty pharmaceutical company in the United States," Salix president and CEO Carolyn Logan said. "The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties."